DTx WEST 2020

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Mark Bini is the Vice President of Innovation and Member Experience at Express Scripts. Since 2008, Mark has been a key contributor to the advancement of Express Scripts’ solution portfolio. Over this time, he has worked with other thought leaders to design and employ an industry-leading, behavior-centric approach to innovation that places clients and members in the “front seat” of product development. Mark is also responsible for Express Scripts’ suite of digital therapeutic solutions that includes remote monitoring solutions for diabetes, asthma, and medication non-adherence. Mark’s approach to innovation and the solutions that have spawned from it have played a key role in Express Scripts being named to Forbes’ World’s Most Innovative Companies.

Anil is a physician executive based in the Boston area and has over 20 years of global healthcare and biopharmaceutical experience. He studied medicine in Ireland and worked clinically in the Irish healthcare system before moving to the biopharmaceutical industry where he has held roles of increasing responsibility across different companies, different therapeutic areas and different geographies.

Anil’s interest in developing world healthcare started while he was studying medicine at the Royal College of Surgeons in Ireland, where he raised money to purchase medical supplies for a rural health clinic in Tanzania, East Africa, and delivered them personally as well as working in the clinic for 3 months. More recently he has been instrumental in establishing a charitable access program to rare disease medicines which is now operating across 10 countries.

Trina has built an extensive career in addressing prevention, wellbeing, behavior change, and emotional health by translating evidence into practice in healthcare in Ireland and the USA. Trina has been working in the digital space since 2010.

Trina is a Senior Principal Consultant in Prevention, Wellness, and Digital Health at Kaiser Permanente’s Care Management Institute. Trina obtained a Ph.D. in health psychology from University College Cork, Ireland. Trina has published on the topic of Obesity and has spoken at numerous conferences. Trina has consulted on games for health, including Kaiser Permanente’s “Amazing Food Detective” and on tech solutions for weight management (Picture it!) in collaboration with Ayogo. Trina is currently co-lead for Project Chamai (Greek for “grounded”) to deploy an ecosystem of digital mental health tools in Kaiser Permanente to support emotional wellness.

Trina has been invited to act as an expert advisor and to educate numerous organizations, including the Centers for Disease Control, CMS, National Committee for Quality Assurance (NCQA), National Quality Forum (NQF), Prescription for Physical Activity Task Force, and the Obesity Society and Ayogo. Trina is a member of the Society for Behavioral Medicine (SBM), the American Psychological Association (APA), The Obesity Society (TOS), and Digital Medicine Society (DiME).

Trina enjoys bringing the evidence to life for front line teams and implementing technology solutions to support people on their journey toward health.

Kal Patel has over 20 years of experience in pharma, medtech and regulated digital health. Prior to joining BrightInsight, he was Chief Commercial Officer for Doctor on Demand, now the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.

Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of digital products in connected devices, advanced algorithms/decision making and next-generation marketing, where he launched multiple regulated devices. Kal also serves as a Senior Advisor in Digital Health to the Boston Consulting Group and various digital health startups

Saeju Jeong, CEO and co-founder of Noom, is a serial entrepreneur and tech company angel investor. Noom is the world’s largest behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of thousands of personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom’s behavior change courses, and Noom’s platform is already being used by leading healthcare and pharmaceutical companies like Novo Nordisk to improve treatment outcomes for patients worldwide. 

Noom, Inc. is backed by Sequoia Capital, RRE, Samsung and Qualcomm.

Kara Tibbe leads health system wide care transformation initiatives centered around digital health innovation. At Spectrum Health, she leads projects focused on virtual and mobile health integration within primary and specialty care. Spectrum Health is the first health system in the US to integrate IQVIA’s App prescription platform “AppScript” into the EMR which enables mobile app prescriptions to be embedded into clinician workflow, a project that Kara leads.  Kara’s role encompasses vetting digital therapeutics for employer and health care settings and operationalizing into seamless patient care.

Her background is in Business Administration and Science.

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Rebecca Lyons is a program manager on Blue Shield of California’s Enhanced Clinical Program & HealthCare value solutions team . Prior to a brief time away to work on patient engagement at a biotech startup, she coordinated the partnerships with medical groups and hospitals while a program manager on BSC’s Accountable Care Organization team. Prior to BSC, she held various positions in health care delivery such as performance improvement, program management and clinical research coordinating at various institutions such as Cedars-Sinai Health System, Rady Children’s Hospital, San Diego and Columbia-NY Presbyterian Hospital. She holds an undergraduate degree in Developmental Psychology from UC San Diego and an MPH from Columbia University.

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.

Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.

With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp’s US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.

In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

Sharief Taraman, M.D. is the Chief Medical Officer at Cognoa, Inc., a Silicon Valley based startup that develops artificial intelligence-based digital diagnostics and personalized therapeutics that provide accurate, earlier diagnoses and more effective treatments to improve outcomes and lower behavioral healthcare costs. He is a Magna Cum Laude graduate of the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine in 2006 and went on to complete residency training in Pediatrics and Pediatric Neurology at the Children’s Hospital of Michigan. Dr. Taraman is dual board certified in Neurology with special qualifications in child neurology from the American Board of Psychiatry and Neurology and in Clinical Informatics from the American Board of Preventative Medicine. He remains clinically active as the Division Chief of the CHOC Children’s Specialists Pediatric Neurology Division and a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine. Dr. Taraman is active in the community as a board member of the AAP Orange County Chapter, Irvine Unified School District Medical Advisory Board, and volunteering for Girl Scouts of Orange County and the Capistrano Unified School District.

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.